Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Reaching a consensus on early TNBC treatment guidelines

Marleen Kok • 13 Mar 2025
BCC 2025
Breast Cancer

Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands, comments on the importance of adjuvant immunotherapy after neoadjuvant immunotherapy in triple-negative stage 2 and 3 breast cancer. Dr Kok also emphasizes the need for biomarkers to select patients who may not benefit from chemotherapy in stage 1 triple-negative breast cancer, where treatment outcomes are generally good, as well as ER-low breast cancer. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marleen Kok

Optimizing immunotherapy for triple-negative breast cancer
0:47
Optimizing immunotherapy for triple-negative breast cancer
Marleen Kok • 13 Mar 2025
Assessing who can benefit from immunotherapy in ER+ breast cancer
1:13
Assessing who can benefit from immunotherapy in ER+ breast cancer
Marleen Kok • 13 Mar 2025
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO
1:08
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO
Marleen Kok • 16 Mar 2023
Personalizing approaches in early-stage TNBC
0:58
Personalizing approaches in early-stage TNBC
Marleen Kok • 16 Mar 2023

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals